In March 2019, the Queenstown Molecular Biology Meeting, themed ‘Drug Discovery and Technological Innovation,’ was held in Shanghai. The scientific meeting was co-chaired by Professor Ming-Wei Wang, director of the National Center for Drug Screening, and Professor Peter Shepherd of the University of Auckland, New Zealand. Professor Daniel Drucker of the University of Toronto, Canada, delivered a special presentation on GLP-1 receptor agonists for diabetes and metabolic disease, drawing considerable interest. …
Summary: With GLP-1 medicines entering the ADA–EASD guidelines as first-line treatments for type 2 diabetes, substantial market demand is expected. Long-acting, human-derived GLP-1 medicines offer glucose-lowering efficacy comparable to insulin, with a very low risk of hypoglycemia. Their weight-loss and cardiovascular benefits can also provide greater benefit for patients receiving long-term GLP-1 treatment. People with type 2 diabetes require lifelong medication. Physicians must consider individual factors that materially affect treatment, including self-care, comorbidities and the burden of paying for medication over the long term. Overall, the market needs high-quality, low-cost, affordable diabetes medicines with multiple effects that improve metabolic syndrome and quality of life. Long-acting, human-derived GLP-1 medicines are expected to become a major force in the diabetes market.
Source: Bioon, ‘GLP-1 medicines may replace insulin as the preferred first-line treatment for type 2 diabetes.’ For details, see http://news.bioon.com/article/6741792.html？从 = singlemessage & isappinstalled = 0